Paul L. Berns, Chief Executive Officer, stated that Neumora "prioritized obesity as the lead indication for NMRA-215, our highly brain-penetrant NLRP3 inhibitor." He outlined, "We expect to have up to ...
Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to investors@xenon-pharma.com. Click to enlarge A live webcast of the webinar will be available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results